Literature DB >> 29072851

Cervical cancer treated with reduced-volume intensity-modulated radiation therapy base on Sedlis criteria (NCCN VS RTOG).

Hua-Chun Luo1, Gui-Shan Lin2, Shao-Guang Liao1, Feng-Mei Wang3, Hui-Hua Cheng1, Jing Feng1, Qin Yin4, Qun-Hua Chen4, Jin-Feng Zhu2, Jian-Feng Xu5, Dian Wang6, Zhi-Chao Fu1.   

Abstract

OBJECTIVE: This study aimed to evaluate the clinical efficacy of different target volumes in pelvic radiotherapy in postoperative treatment of cervical cancer based on the Sedlis criteria.
METHODS: Patients who admitted to our department for post-operative radiotherapy of cervical cancer from December 2001 to December 2011 and met the Sedlis criteria were retrospectively analysed. The incidences of acute and late radiation injuries, and overall, disease-free and tumour-specific survival with reduced-volume pelvic and whole-pelvis radiotherapy were evaluated and compared.
RESULTS: A total of 371 patients were included in the study, including 239 receiving whole-pelvis radiotherapy and 132 receiving reduced-volume pelvic radiotherapy. The volume of contours for mean PTV volumes, bilateral femoral heads and small intestine volumes in reduced-volume pelvic radiotherapy were lower than whole-pelvis radiotherapy; the results were similar to the V10, V20, V30, V40 and V45 for pelvic bone marrow and small intestine dose volume (both p < 0.05). The acute radiation injury observed in the two groups was mainly haematologic toxicity and upper and lower gastrointestinal symptoms. The incidences of acute radiation injury, and late radiation injury of gastrointestinal and urinary tracts were both significantly lower with reduced-volume pelvic radiotherapy than with whole-pelvis radiotherapy (both p < 0.05). Moreover, there was no significant difference in the incidence of lower extremity oedema, or 2-year or 5-year overall, disease-free or tumour-specific survival between groups (all p > 0.05).
CONCLUSION: Reduced-volume pelvic radiotherapy could relieve acute and late radiation injuries, especially myelosuppression, and did not affect long-term survival. Advanced in knowledge: Our study shows that reduced-volume base on National Comprehensive Cancer Network 2016 is more fit for cervical cancer than others.

Entities:  

Mesh:

Year:  2017        PMID: 29072851      PMCID: PMC5966210          DOI: 10.1259/bjr.20170398

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  29 in total

1.  Individualized nonadaptive and online-adaptive intensity-modulated radiotherapy treatment strategies for cervical cancer patients based on pretreatment acquired variable bladder filling computed tomography scans.

Authors:  M L Bondar; M S Hoogeman; J W Mens; S Quint; R Ahmad; G Dhawtal; B J Heijmen
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-01-21       Impact factor: 7.038

2.  20 year experience of postoperative radiotherapy in IB-IIA cervical cancer patients with intermediate risk factors: impact of treatment period and concurrent chemotherapy.

Authors:  Sanghyuk Song; Changhoon Song; Hak Jae Kim; Hong-Gyun Wu; Jin Ho Kim; Noh-Hyun Park; Yong-Sang Song; Jae Weon Kim; Soon-Beom Kang; Sung W Ha
Journal:  Gynecol Oncol       Date:  2011-10-18       Impact factor: 5.482

Review 3.  Unusual localizations of sentinel lymph nodes in early stage cervical cancer: a review.

Authors:  Lobna Ouldamer; Henri Marret; Olivier Acker; Isabelle Barillot; Gilles Body
Journal:  Surg Oncol       Date:  2012-05-16       Impact factor: 3.279

Review 4.  Late effects consensus conference: RTOG/EORTC.

Authors: 
Journal:  Radiother Oncol       Date:  1995-04       Impact factor: 6.280

5.  Intensity-modulated whole pelvic radiotherapy provides effective dosimetric outcomes for cervical cancer treatment with lower toxicities.

Authors:  Y Lv; F Wang; L Yang; G Sun
Journal:  Cancer Radiother       Date:  2014-11-18       Impact factor: 1.018

6.  Mapping pelvic lymph nodes: guidelines for delineation in intensity-modulated radiotherapy.

Authors:  Alexandra Taylor; Andrea G Rockall; Rodney H Reznek; Melanie E B Powell
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-09-29       Impact factor: 7.038

7.  A phase III randomized trial of postoperative pelvic irradiation in Stage IB cervical carcinoma with poor prognostic features: follow-up of a gynecologic oncology group study.

Authors:  Marvin Rotman; Alexander Sedlis; Marion R Piedmonte; Brian Bundy; Samuel S Lentz; Laila I Muderspach; Richard J Zaino
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-01-19       Impact factor: 7.038

8.  Prospective multi-institutional study of definitive radiotherapy with high-dose-rate intracavitary brachytherapy in patients with nonbulky (<4-cm) stage I and II uterine cervical cancer (JAROG0401/JROSG04-2).

Authors:  Takafumi Toita; Shingo Kato; Yuzuru Niibe; Tatsuya Ohno; Tomoko Kazumoto; Takeshi Kodaira; Masaaki Kataoka; Naoto Shikama; Masahiro Kenjo; Sunao Tokumaru; Chikako Yamauchi; Osamu Suzuki; Hideyuki Sakurai; Hodaka Numasaki; Teruki Teshima; Masahiko Oguchi; Yoshikazu Kagami; Takashi Nakano; Masahiro Hiraoka; Norio Mitsuhashi
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-04-04       Impact factor: 7.038

9.  Cancer statistics in China, 2015.

Authors:  Wanqing Chen; Rongshou Zheng; Peter D Baade; Siwei Zhang; Hongmei Zeng; Freddie Bray; Ahmedin Jemal; Xue Qin Yu; Jie He
Journal:  CA Cancer J Clin       Date:  2016-01-25       Impact factor: 508.702

10.  Image guided adaptive brachytherapy with combined intracavitary and interstitial technique improves the therapeutic ratio in locally advanced cervical cancer: Analysis from the retroEMBRACE study.

Authors:  Lars Fokdal; Alina Sturdza; Renaud Mazeron; Christine Haie-Meder; Li Tee Tan; Charles Gillham; Barbara Šegedin; Ina Jürgenliemk-Schultz; Christian Kirisits; Peter Hoskin; Richard Pötter; Jacob C Lindegaard; Kari Tanderup
Journal:  Radiother Oncol       Date:  2016-04-21       Impact factor: 6.280

View more
  3 in total

1.  Experimental Study and Clinical Observation on the Improvement Effect of Lienal Polypeptide on Blood Toxicity and Immune Injury Induced by Radiotherapy.

Authors:  Alan Chu; Rui Song; Ge Hou; Jinjin Yuan; Cheng Wang; Yu Yang; Ning Qin; Yaohe Liu; Bing Liang; Yan Zhang; Zongwen Liu
Journal:  Genet Test Mol Biomarkers       Date:  2020-02

2.  Radiation Therapy for Cervical Cancer: Executive Summary of an ASTRO Clinical Practice Guideline.

Authors:  Junzo Chino; Christina M Annunziata; Sushil Beriwal; Lisa Bradfield; Beth A Erickson; Emma C Fields; KathrynJane Fitch; Matthew M Harkenrider; Christine H Holschneider; Mitchell Kamrava; Eric Leung; Lilie L Lin; Jyoti S Mayadev; Marc Morcos; Chika Nwachukwu; Daniel Petereit; Akila N Viswanathan
Journal:  Pract Radiat Oncol       Date:  2020-05-18

3.  Post-operative small pelvic field radiation therapy in patients with intermediate risk early stage cervix cancer: a safe and efficient treatment modality.

Authors:  José Antonio Solis; Ilan Perrot Rosenberg; Jorge Olivares; Benjamin Tudela; Gabriel Veillon; Gabriel Lazcano
Journal:  Rep Pract Oncol Radiother       Date:  2021-06-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.